Get started
Author

Anju Shrestha

ORCID: 0000-0001-5945-841X
Observed ORCID: 0000-0001-5945-841X
OpenAlex ID: A5102983024
Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
2016 · Malini DeSilva, Flor M. Munoz, et al. · Vaccine · 160
PDF
Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation
2017 · Malini DeSilva, Flor M. Munoz, et al. · Vaccine · 72
PDF
Neonatal seizures: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
2019 · Serena Pellegrin, Flor M. Munoz, et al. · Vaccine · 67
PDF
Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
2021 · Stephanie Pepin, Jean-François Nicolas, et al. · Human Vaccines & Immunotherapeutics · 38
PDF
Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial
2021 · Rosalind Hollingsworth, Arto Palmu, et al. · American Heart Journal · 15
PDF
Exposure to quadrivalent influenza vaccine during pregnancy: Results from a global pregnancy registry
2021 · Shaleesa Ledlie, Sonja Gandhi‐Banga, et al. · Influenza and Other Respiratory Viruses · 10
Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
2022 · Sonja Gandhi‐Banga, Sophie Wague, et al. · Influenza and Other Respiratory Viruses · 9
PDF
Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial
2023 · Leilani Sanchez, Takahiro Nakama, et al. · Vaccine · 8
Safety and Efficacy of Linvoseltamab (LINVO) in Patients (Pts) with High-risk Smoldering Multiple Myeloma (HR-SMM): First Results from the Phase 2 LINKER-SMM1 Trial
2025 · Paula Rodríguez-Otero, Juan José Bargay Lleonart, et al. · Clinical Lymphoma Myeloma & Leukemia · 7
Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial
2021 · Lee-Jah Chang, Evan J. Anderson, et al. · Vaccine · 5
PDF
Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)
2026 · Dan Chalothorn, Aaron P. Kithcart, et al. · Blood · 3
PDF
In Vitro Measurements of Glucose Consumption and Glycated Hemoglobin in Whole Blood Exposed to Glucose and Various Temperatures
2024 · Anju Shrestha, Krystal Smith, et al. · International Journal of Clinical Chemistry and Laboratory Medicine · 1
PDF
Supplementary Table S4 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Figure S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Methods S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Table S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Data from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Figure S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Figure S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Table S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Supplementary Table S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al.
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
2026 · Attaya Suvannasankha, Mengying Li, et al. · Clinical Cancer Research
Second primary malignancy (SPM) in patients (pts) with multiple myeloma (MM) receiving chimeric antigen receptor T-cell (CAR T) therapy or other systemic anticancer therapy (SACT): A comparative study using a real-world database.
2025 · Attaya Suvannasankha, Mengying Li, et al. · Journal of Clinical Oncology
Author response for "Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22"
2022 · Sonja Gandhi‐Banga, Sophie Wague, et al.
160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age
2020 · Leejah Chang, Evan J Anderson, et al. · Open Forum Infectious Diseases
Works count: 25
Citation count: 395
H-index: 8
I10-index: 6
Year
Topic
Type